P. Cooke, State, markets and networks in bioeconomy knowledge value chains, pp.163-80, 2009.

H. C. Stoeklé, M. F. Mamzer-bruneel, and G. Vogt, 23andMe: a new two-sided data-banking market model, BMC Med Ethics, vol.17, p.11, 2016.

, Committee on cancer clinical trials and the NCI cooperative group program, board on health care services-Institute of medicine. A national cancer clinical trials system for the 21 st century: reinvigorating the NCI cooperative group program, p.298, 2010.

L. Kalokairinou, H. C. Howard, and P. Borry, Current developments in the regulation of direct-to-consumer genetic testing in Europe, Med Law Int, vol.15, pp.97-123, 2015.

L. Hennen and A. Sauter, Van den Cruyce E. Direct to consumer genetic testing study. Brussels : Parlement européen, 2008.

B. Jordan, Les tests génétiques grand public en caméra cachée, Med Sci (Paris), vol.27, pp.103-109, 2011.

H. C. Stoeklé, N. Forster, and M. Turrini, La propriété des données génétiques : de la donnée à l'information, Med Sci, vol.34, pp.1100-1104, 2018.

P. Borry, L. Henneman, and P. Lakeman, Preconceptional genetic carrier testing and the commercial offer directly-to-consumers, Hum Reprod Oxf Engl, vol.26, pp.972-979, 2011.

D. Bourcier, D. Filippi, and P. , Vers un droit collectif sur les données de santé, Rev Droit Sanit Soc RDSS Dalloz Rev, vol.3, pp.444-56, 2018.

H. C. Howard and P. Borry, Is there a doctor in the house? The presence of physicians in the direct-to-consumer genetic testing context, J Community Genet, vol.3, pp.105-117, 2012.

. Ebpb, Guidelines 2/2018 on derogations of article 49 under regulation 2016/679. European Data Protection Board, 2018.

H. Jautrou and M. P. Bès, une innovation sanitaire régulée par le marché ? In : Valat B, ed. Les marchés de la santé en France et en Europe (XIX e -XX e siècle). Toulouse : Presses Universitaires du Midi, 2000.

H. Jautrou, Les tests génétiques vendus en libre accès sur l'Internet : une médicalisation sans médecin ? Thèse de doctorat de sociologie, 2016.

K. L. Wrick, Markets research. Direct-to-consumer genetic testing: business prospects in the United States, 2009.

. Gppc, Survey of direct-to-consumer testing statutes and regulations. Genetics and public policy center, 2007.

P. Borry, R. E. Vann-hellemondt, and D. Sprumont, Legislation on direct-to-consumer genetic testing in seven European countries, Eur J Hum Genet, vol.20, pp.715-736, 2012.

B. Jordan, Les tests génétiques grand public ont-ils une utilité clinique ?, Med Sci, vol.28, pp.325-333, 2012.

P. Ducournau, P. A. Gourraud, and E. Rial-sebbag, Tests génétiques en accès libre sur Internet : stratégies commerciales et enjeux éthiques et sociétaux, Med Sci, vol.27, pp.95-102, 2011.

P. C. Ng, S. S. Murray, and S. Levy, An agenda for personalized medicine, Nature, vol.461, pp.724-730, 2009.

B. Jordan, Craig Venter et son exome, Med Sci (Paris), vol.24, pp.989-90, 2008.

B. Jordan, Dépistage du cancer : les promesses illusoires de Pathway Genomics, Med Sci, vol.31, pp.1137-1146, 2015.

P. Borry, M. C. Cornel, and H. C. Howard, Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market, J Community Genet, vol.1, pp.101-107, 2010.

S. Klepper, Industry life cycles, Ind Corp Change, vol.6, pp.145-81, 1997.

B. Jordan, Grandes manoeuvres autour des profils génétiques en libre accès, Med Sci (Paris), vol.30, pp.227-235, 2014.

P. M. Saukko, Shifting metaphors in direct-to-consumer genetic testing: from genes as information to genes as big data, New Genet Soc, vol.36, pp.296-313, 2017.

W. W. Powell, K. W. Koput, and D. R. White, Network dynamics and field evolution: the growth of interorganizational collaboration in the life sciences, Am J Sociol, vol.110, pp.1132-205, 2005.

S. J. Kline and N. Rosenberg, National academy of engineering. The positive sum strategy: harnessing technology for economic growth, pp.275-305, 1986.

S. M. Re?fe?rences-1.-sumida, D. M. Truitt, and A. A. Lemckert, Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein, J Immunol, vol.174, pp.7179-85, 2005.

C. Wohlfart, Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms, J Virol, vol.62, pp.2321-2349, 1988.

D. L. Mallery, W. A. Mcewan, and S. R. Bidgood, Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21), Proc Natl Acad Sci, vol.107, pp.19985-90, 2010.

M. Bottermann, S. Foss, and S. L. Caddy, Complement C4 prevents viral infection through capsid inactivation, Cell Host Microbe, vol.25, pp.617-646, 2019.

M. Bottermann, S. Foss, L. M. Tienen, and . Van, TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination, Proc Natl Acad Sci, vol.115, pp.10440-10485, 2018.

J. G. Smith, M. Silvestry, and S. Lindert, Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization, PLoS Pathog, vol.6, p.1000959, 2010.

M. Schmid, P. Ernst, and A. Honegger, Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control, Nat Commun, vol.9, p.450, 2018.

L. A. Rojas, G. N. Condezo, and R. Moreno, Albuminbinding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery, J Control Release, vol.237, pp.78-88, 2016.